Product Overview

Hzymes has independently developed a Biological Fermentation semaglutide intermediate GLP-1(9-37).

Using AI-driven protein engineering, we modified expression strains to increase yield and atomic economy, and developed a highly specific enterokinase cleavage and purification process to achieve high purity and low Impurities, followed by lyophilization. With a complete GMP Quality system and ton-scale production capacity.

Key Features

High Purity

Manufactured to achieve ≥95% purity, supporting downstream semaglutide synthesis requirements.

Low Impurity Profile

Developed using a highly specific enterokinase cleavage and purification process to minimize process-related impurities and improve product consistency.

Scalable Manufacturing

Produced through a biological fermentation process with ton-scale manufacturing capacity to support both development and commercial supply needs.

Global Patent Freedom

Designed to support global market development with a patent-unrestricted supply strategy.

If applicable, it may be advisable to add a disclaimer such as "Customers are responsible for assessing local intellectual property requirements."

GMP Quality System

Manufactured under a comprehensive GMP quality management system, with established controls for traceability and batch-to-batch consistency.

Applications

Semaglutide Synthesis

Used as a key intermediate in the synthesis of semaglutide, supporting the manufacture and development of GLP-1 receptor agonist products.

Process Development and Scale-Up

Suitable for process development, pilot production, and commercial manufacturing workflows related to semaglutide production.

Pharmaceutical Manufacturing

Applicable to organizations seeking a fermentation-derived GLP-1(9-37) intermediate with scalable supply and quality-controlled production.

Performance Data